INGENIA Therapeutics Inc. Korean Depositary Receipt Repr 1 Sh Reg S
KKRX:95026020,700.00
KRW
-2,050.00
(-9.01%)
ISIN
KR8840280000
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sang-Yeul Han
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Watertown United States
- Website
- ingeniatx.com
- Similar Companies
- Business
- INGENIA Therapeutics Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes therapeutic antibody candidates targeting microvascular dysfunction, chronic inflammatory conditions, and oncology indications. The company operates through its proprietary vascular-targeting engineering platforms, including TIE-body, an agonist antibody technology engineered to selectively activate the TIE2 receptor pathway to restore endothelial barrier integrity and stabilize damaged microvessels; and LCIDEC (Ligand Capture & Internalization into Endothelial Cells), a bifunctional platform designed to facilitate vascular stabilization while simultaneously capturing and degrading target disease-driving ligands. The company's clinical and preclinical therapeutic pipeline comprises IGT-427 (MK-8748), a bispecific antibody candidate targeting TIE2 and VEGF for the treatment of retinal vascular disorders such as wet age-related macular degeneration and diabetic macular edema; IGT-303, an antibody therapeutic in clinical evaluation for chronic kidney disease and diabetic nephropathy; IGT-302, an investigational therapy developed for the management of glaucoma; and IGT-532, a preclinical immuno-oncology program directed at microvascular normalization in solid tumors. Founded in 2018, INGENIA Therapeutics Inc. is headquartered in Watertown, Massachusetts, and conducts research, clinical development, and business operations across the United States, South Korea, and Australia. In recent major developments, INGENIA Therapeutics completed its initial public offering on South Korea's KOSDAQ market in August 2026 through the issuance of Korean Depositary Receipts under ticker 950260, raising capital to advance its clinical pipeline. Furthermore, its lead retinal candidate IGT-427, previously out-licensed to EyeBio, transferred to Merck & Co. following Merck's acquisition of EyeBio, advancing the candidate into late-stage global Phase 3 clinical trials.